Sign in

NCT07489586Not yet recruitingPhase 3

A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration

A Multicenter, Randomized, Double-Masked, Active-Controlled, Parallel-Group Phase III Clinical Study to Evaluate the Efficacy and Safety of QL1207H Injection Versus Eylea® (Aflibercept, 114.3 mg/mL, 8 mg Per 70 μL) in Patients With Neovascular Age-Related Macular Degeneration

Source: ClinicalTrials.gov · Last updated 24 Mar 2026

Brief summary (registry, in English)

The goal of this clinical trial is to evaluate the efficacy and safety of QL1207H injection versus aflibercept 8 mg in patients with neovascular age-related macular degeneration. The main question it aims to answer is: • Whether the efficacy and safety of QL1207H and aflibercept 8 mg are similar. Participants will receive injection once every 4 weeks for 3 consecutive doses, followed by injection once every 16 weeks at maximum. Researchers will compare QL1207H group and aflibercept 8 mg group to see if they are similar in improving best corrected visual acuity.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 3
Study type
Interventional
Enrollment
356 (estimated)
First submitted
18 Mar 2026
Start date
1 Mar 2026
Primary completion date
31 Dec 2026
Lead sponsor
Qilu Pharmaceutical Co., Ltd.
NCT number
NCT07489586

What you commit to

  • Study type: Interventional · Phase 3
  • Planned participants: 356
  • From 1 Mar 2026 to the primary completion date, 31 Dec 2026
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Uncontrolled glaucoma (defined as IOP \>25 mmHg despite treatment with antiglaucoma medication) in the study eye.
  • Myopia of a spherical equivalent of at least 8 diopters in the study eye prior to any refractive or cataract surgery.

Other illness

  • Total lesion size \>12 disc areas; or subretinal hemorrhage that is at least 50% of the total lesion area, or if the blood under the fovea is 1 or more disc areas in size in the study eye.

Other

  • Causes of CNV other than nAMD in the study eye.
  • Scar, fibrosis, or atrophy involving the central subfield in the study eye.

Who the study is looking for

  • At least 50 years of age.
  • Active subfoveal CNV secondary to nAMD, including juxtafoveal lesions that affect the fovea as assessed in the study eye.
  • Total area of CNV (including both classic and occult components) must comprise greater than 50% of the total lesion area in the study eye.
  • Presence of IRF and/or SRF affecting the central subfield of the study eye on OCT.
  • BCVA ETDRS letter score of 78 to 24 in the study eye.

Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.